Introduction and aim of the work
Prostate-specific antigen (PSA) is a uniquely valid tumor marker for prostate cancer screening and early detection. 1 The widespread use of serum PSA testing for early prostate cancer detection has increased the proportion of early stage cancers detected and is at least partially responsible for the recent decrease in prostate cancer mortality rates in the United States. 2 Early diagnosis of prostate cancer has been of great value, as younger age is an independent predictor of better prognosis. 3, 4 Moreover, the use of lower PSA cutoffs may detect prostate cancer more frequently in its curable stages. 5 Patients aged less than 50 years were studied before for early cancer detection. Many authors suggested that a lower PSA cut-off point to screen this group of patients (PSA 2-2.5 ng ml
À1
) was applicable to this age-group of patients. [6] [7] [8] Thus, the need to confirm the concept of lowering PSA level as a screening tool for younger patients is warranted. Moreover, validation and reproducibility of using a certain lower PSA cut-off point are mandatory. We aimed to analyze the incidence and occurrence of prostatic adenocarcinoma in patients less than 50 years old with serum PSA 2-2.5 ng ml
.
Materials and methods
Pathological evaluation of nonsymptomatic young patients (o50 years) with low PSA (p4 ng ml
À1
) in the community is a difficult task.
To overcome this obstacle, between January 2006 and January 2008, 355 men who underwent radical cystoprostatectomy for invasive bladder cancer were retrieved. Among them, 162 cases were not associated with radiological and/or pathological prostatic invasion by bladder cancer. Random selection of 56 pairs of cases, with PSA p4 ng ml
, based on age (more or less than 50 years) was carried out. The selected patients were divided into two groups: group A: less than 50 years, and group B: more than 50 years; there were 56 cases in each group.
The resected prostate glands of the selected cases were examined pathologically for malignancies. Correlation of PSA, digital rectal examination (DRE), body mass index (BMI) and pathological findings was analyzed.
Data were processed using SPSS 11.0 for Windows (SPSS Inc., Chicago, IL, USA). Statistical analysis of continuous variable means was performed using Student's t-tests (paired and unpaired, when appropriate). Pearson's test was carried out to detect the correlation coefficient between tested variables. Analysis of noncontinuous variables was performed using the w 2 -test. A P-value of o0.05 was considered statistically significant.
Results
Among 355 cases of radical cystoprostatectomy specimens, 162 were locally confined bladder cancer cases without a radiological and/or pathological prostatic invasion.
Within the patients with serum PSA p4 ng ml À1 and based on the age 50 years, random selection of an two equal groups was carried out. The total number of cases was 112, which were divided into two groups. Each group had 56 cases: group A p50 years, and group B 450 years.
The age range of group A was 32-50 years (mean±s.d.: 46.17±4.3 years) and that of group B was 51-68 years (mean ± s.d.: 58.42 ± 4.4 years) The mean PSA was 1.9±1.6 ng ml À1 in group A and 2±1.6 ng ml À1 in group B. In the majority of cases (90.4%), DRE had been of normal prostatic feelings without nodules or surface irregularities (P40.05).
In group A, prostatic adenocarcinoma was detected in 1.8% of cases (one case; PSA 2.3 ng ml À1 ) and high-grade prostatic intraepithelial neoplasia (HG-PIN) was detected in 11 cases (19.6%). Conversely, six cases (10.6%) of prostatic adenocarcinoma and four cases of HG-PIN (7.1%) were detected in group B. Table 1 showed the pathological distribution of the two groups.
On analysis of malignant and HG-PIN pathology compared to other pathologies, statistically significant difference in prostate cancer detection was weak between the two age groups (P ¼ 0.051). However, it was not statistically significant with HG-PIN (P ¼ 0.079) but clinically significant (11 versus 4 cases; that is approximately a threefold increased detection rate within group A), as shown in Tables 2 and 3 .
To validate the values of PSA, further analysis of the data based on PSA cut-off points 2 and 2.5 ng ml À1 was carried out (Tables 4 and 5 ).
The analysis of data within the two age groups when PSA ranged between 2 and 2.5 ng ml À1 did not show any significant difference between groups. However, on clinical base, at PSA (p2.5 ng ml À1 ), 8 out of a total 11 HG-PIN cases (72.7%) were detected in the younger patient group.
Moreover, on a PSA cut-off point of 2.5 ng ml À1 in younger patients (p50 years), only one out of a total seven cases of prostatic adenocarcinoma (14.28%) was missed, which was not missed when the PSA cut-off point was 2 ng ml À1 . BMI was calculated and correlation within the age group was assessed. In group A, the mean BMI was 27.8±4.4, whereas in group B it was 27.5±4.8.
Interestingly, there was a direct significant correlation between PSA and BMI in group A (CC: 0.5, P ¼ 0.015), whereas it was not correlated in group B (CC: 0.16, P ¼ 0.239) ( Table 6 ).
Discussion
The use of PSA as a screening tool has been directed toward the early stage detection of prostate cancer;
1 it Need for lowering PSA cutoff point IA Hekal has been confirmed that being younger at diagnosis is an independent predictor of a better prognosis. 3, 4 Therefore, the use of lower PSA cutoffs may detect prostate cancer more frequently in its curable stages. 5 As few as 25% of men with a PSA level of 4-10 ng ml À1 have prostate cancer, and up to 25% of men with a PSA of o4 ng ml À1 will have prostate cancer. [9] [10] [11] This poor specificity prompted the introduction of age-adjusted PSA level thresholds. 6 Furthermore, as the incidence of benign prostatic hyperplasia (BPH) increases from 9% in men aged o60 years to 17% in men aged 460 years, screening younger men should result in fewer falsepositive results. 12 Many authors hypothesize that lowering the PSA level thresholds in men aged o50 years would result in increased detection and treatment of early stage prostate cancer, which would potentially affect the length of their lives. 8 Catalona et al. 5 recommended a lower PSA value of 2.6 ng ml
À1
, irrespective of the age, which increases the value of early detection of curable cases and therefore increases the chances of cure. However, Oesterling et al. 6 and Moul et al. 7 suggested that the upper limit of normal PSA in men aged 40-49 years was 2.5 and 2.0 ng ml À1 , respectively.
Indolent prostate cancer that may be pronounced in an aggressive manner later prompted several studies to suggest the potential advantages of lower PSA cutoffs. [13] [14] [15] [16] Gann et al. 13 reported that compared with men whose PSA levels were less than 1 ng ml
, those with PSA levels of 2.01-4.0 ng ml À1 were 5.5-8.6 times more likely to develop aggressive prostate cancer within 10 years.
Sun et al. 6 defined three main reasons that make PSA screening with a lowered threshold useful in men aged 40-49 years. First, the incidence of BPH is lower in young men. 9 Second, PSA screening in younger men is more likely to detect men with curable, clinically localized cancer. Finally, younger men are less likely to have significant medical comorbidities and more likely to opt for definitive treatments such as surgery.
In our study, we aimed to validate this concept and test its reproducibility to use a PSA cut-off point: 2-2.5 ng ml À1 in the group of patients (less than 50 years) with nonprostatic symptoms and with definitive prostatic pathological evidence.
Although the younger men may have fewer symptoms, pathological screening is not easy to do. We overcome this methodological problem by selecting radical cystoprostatectomy cases in our institute. After omitting the cases that had a radiological and/or pathological prostatic invasion by bladder cancer, random selection of 56 pairs into two groups (more or less than 50 years) was carried out.
Among our 112 patients with PSA p4 ng ml
, 7 cases (6.25%) of prostatic adenocarcinoma were detected in the definitive pathological analysis of the prostate (one in group A (p50 years) and 6 in group B (450 years)). This incidence is correlated with Colberg et al., 17 who diagnosed prostate cancer in 7% of screened peoples with PSA p4 ng ml À1 in their initial biopsy, and in the European trial it was 4%. Need for lowering PSA cutoff point IA Hekal
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High-grade PIN showed a high prevalence in our total patients of 15 cases (13.4%), the majority of them in the younger group (73.3%), which was in need of a meticulous follow-up, as 20% of low PSA cases may develop prostate cancer on long follow-up. 19 Analysis of malignant changes versus other pathologies has a weak statistical significance. HG-PIN was clinically different (11 versus 4 cases in groups A and B, respectively), but it was not statistically different, whereas precancerous lesions such as low-grade prostatic intraepithelial neoplasia (LG-PIN) and atypical acinar proliferation were detected in seven (12.5%) and six (10.8%) cases in groups A and B, respectively.
Interestingly, with analysis of malignant pathology with PSA at 2 and 2.5 ng ml À1 , one case out of seven (14.26%) was missed at a cutoff of 2.5 ng ml À1 in the whole study group, and it is unfortunate that we missed the only case in the younger group. Moreover, at PSA of 2.5 ng ml À1 , 8 out of 11 cases (72.7%) of HG-PIN in the younger age group will be lost.
PSA and obesity are still a matter of controversy in the literature. An inverse relation between PSA and BMI is a conclusion in American, Japanese and Korean patients. Many authors showed an inverse relation between PSA and BMI. [20] [21] [22] In contrast, our study showed a directly weak but significant relation in younger patients, whereas it was insignificantly correlated in the age group 450 years.
To the best of our knowledge, few reports in English literature discuss reproducibility and validate the use of lower PSA in young patients (less than 50 years). Our study confirms this principle and recommends the use of PSA cut-off points of 2 ng ml À1 for screening and biopsy advice level for younger patients rather than 2.5 ng ml
À1
to avoid missing 14.28% of positive cases in this age group.
Conclusion
A new serum PSA for patients less than 50 years old is required for screening and early cancer detection.
On the basis of our study, serum PSA 2 ng ml À1 seems to be a valid cut-off point to screen patients less than 50 years (to avoid missing 14.26% of positive cases at PSA 2.5 ng ml À1 ). HG-PIN was pathologically detected in 19.6% of this age group, which needs a meticulous follow-up for that premalignant condition.
Interestingly, serum PSA in younger patients has a direct correlation with BMI.
